Granules India ltd has received a license from Medicines Patent Pool (MPP) to manufacture and market generic versions of Pfizer’s oral treatment nirmatrelvir which will be copackaged with ritonavir for treatment of COVID-19. The licenses are applicable for both active pharmaceutical ingredients (API) and finished products, in tablet form, of nirmatrelvir; ritonavir.
- Read more about Granules India receives license to market Paxlovid of Pfizer
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2022/granules-india-receives-license-to-market-paxlovid-of-pfizer
No comments:
Post a Comment